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Abstract Background and Objective: Drug-drug interaction (DDI) is an important
aspect of drug development, especially for safety. When a drug is used
concomitantly with other drug(s), one of the major concerns is the change of
exposures, including the rate and extent of drug absorption, distribution,
metabolism and elimination. To address the concerns, a common practice is
to measure and report the differences between the exposure in the presence
and in the absence of concomitant medication (COMED). The area under
the plasma concentration versus time curve (AUC), maximum plasma con-
centration (Cmax) and time to reach the Cmax (tmax) changes are usually
measured in DDI studies. A usual observation is the different extents of
changes among AUC, Cmax and tmax, which may raise concerns in certain
therapeutic areas or some special agents. The objective of this study was to
investigate the variation among changes of AUC, Cmax and tmax in DDI
studies, and its pharmacokinetic manifestation.
Data Sources: Based on a list of DDI results from the literature, with the
assumptions that the primary parameters of a drug of interest were altered
during a DDI, two sets of simulated data were generated according to a single
oral dose, one-compartment model. The first set including 24 cases with dif-
ferent half-lives and absorption constants (ka) considered the exposure
changes upon independent variation of bioavailability (F), clearance (CL),
volume of distribution (Vd) and ka up to 50-fold increases or decreases. The
second set considered the exposure changes with simultaneous variation of F,
CL, Vd, and ka within 5-fold range (increase or decrease) for a case selected
from the first set.
Study Selection, Data Extraction and Synthesis: Parameter fold changes
(defined in a fashion showing fold increase or fold decreases, including CL
fold change, F fold change, Vd fold change and ka fold change) and exposure
changes (AUC fold change, Cmax fold change, tmax fold change and fold
change difference [AUC fold change - Cmax fold change]) were used to gen-
erate plots demonstrating various relationships between parameter fold
changes and exposure changes. Based on the observations that AUC was
influenced by CL and F, Cmax was affected by all four parameters, tmax was
mainly determined by CL and ka, F did little for tmax and ka was unrelated to
AUC, a chart was created for DDI pattern recognition.
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Conclusion: An approach, named DDI pattern recognition, is proposed
for didactical purposes. It provides a quick initial estimate for interpreting
the DDI results based on the exposure changes. This approach entails the
following stages: (i) performing a drug interaction study; (ii) calculating
the exposure changes in the presence of COMED compared to those in the
absence of COMED, and the fold change difference; (iii) selecting the para-
meter fold changes that may play important roles in a specific DDI, by
estimating their possible ranges; and (iv) interpreting the DDI by integrating
all the information available, such as the possible mechanism involved.
A quicker and better understanding about the processes, which dominate a
DDI, has been achieved using this approach by focusing on integration of all
information available and mechanistic interpretation.
Introduction
Drug-drug interaction (DDI) is an important
aspect of drug development. When a drug is used
concomitantly with other drug(s), one of the
major concerns is the change of exposures, in-
cluding the rate and extent of drug absorption,
distribution, metabolism and elimination. To
address these concerns, a common practice is
to measure the exposure and report its increases
(or decreases) when the drug is used in the pre-
sence of concomitant medication (COMED)
compared to that when it is used alone.
In vivoDDI studies are generally designed in a
crossover fashion to compare the exposures of
the drug of interest with and without COMED.
Most often, the differences of the exposures are
based on the following three measures: (i) area
under the plasma concentration versus time
curve (AUC), a measure of the total exposure;
(ii) maximum plasma concentration (Cmax), a
measure of the extent of the exposure; and (iii) time
to the Cmax (tmax), a measure of the rate of the
exposure.
These exposure measures are usually obtained
by non-compartmental analysis,[1] which is
simple and accurate. Cmax and tmax are directly
observed from the plasma concentration versus
time curve. As long as the sampling times are
appropriately selected, these two values can be
adequately captured. If the sampling times are
long enough, AUC is estimated from zero to
the last measured timepoint (e.g. 24 hours after
dosing) using the linear trapezoidal rule or elated
methods,[1] such as log trapezoidal method.
Usually, it is extrapolated from the last measured
timepoint to infinity by incorporating the elim-
ination rate constant, which describes the rate of
drug removal from the body.[1]
When comparing the exposures between the
presence and absence of COMED, a usual ob-
servation is the inconsistent changes between
AUC and Cmax in a specific DDI study. For ex-
ample, cases observed in the literature are pre-
sented in table I.
As seen, not only the exposure folds vary, but
the relative folds between AUC and Cmax for the
same interaction differ as well. Roughly, the re-
lative fold changes between AUC and Cmax can
be classified into three categories. In the first
category, AUC and Cmax have similar fold
changes during DDI.[2,3] The second category
includes the cases in which AUC has larger fold
changes compared to Cmax.
[4-8] In cases of the
third category, Cmax has larger fold changes
compared with AUC.[9-18]
It is interesting to note that rosuvastatin in
three different studies with three different con-
comitant medications (gemfibrozil,[6] lopinavir/
ritonavir[7] and ciclosporin,[8] respectively)
showed similar pattern with Cmax having higher
fold changes compared to AUC fold changes,
although the absolute fold changes were different
(2.21, 4.7 and 10.6 for Cmax, respectively). On the
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other hand, gemfibrozil as a COMED in another
study[15] caused AUC and Cmax fold changes of
repaglinide following another pattern: AUC was
much higher than Cmax (7 vs 2). The difference
was even larger in a study where salmeterol had
16-fold AUC in the presence of ketoconazole,
whereas the Cmax fold change was only 1.4.
[18]
Also note that tmax change was positive (increase)
in some situations and negative (decrease) in
others.
In some cases, AUC and Cmax changes could
be in the opposite directions. For example, full
dose of amprenavir and nelfinavir resulted in
decrease in amprenavir Cmax by 14%, but increase
in AUC by 46%.[19] In another report, 14 healthy
volunteers (7 male, 7 female) received single oral
0.5mg doses of the anticholinergic agent scopo-
lamine in a randomized crossover fashion with
either 250mL of water or fresh-squeezed, single-
strength grapefruit juice. In the presence of
grapefruit juice, scopolamine Cmax was decreased
11%, while AUC was increased 35%, and time to
peak level (tmax) was extended from 23.5 minutes
to 59.5 minutes (153% increase)[20] compared
with water.
This difference of fold changes between AUC
and Cmax could be of concern. For certain drug
effects, the Cmax is an important consideration
while under other circumstances, AUC is im-
portant. If a clinical outcome is most closely re-
lated to drug concentration (e.g. tachycardia with
sympathomimetics), the exposure measure, Cmax,
may be the most important to consider. Con-
versely, if the clinical outcome is related more to
extent of exposure, AUCwould be preferred[21] in
the context that a long, low concentration ex-
posure may be as important as shorter but higher
concentration.
Table I. Exposure changes due to drug-drug interactions reported in the literature
Drug of interesta COMED AUC foldb Cmax fold
b tmax change (h) Reference
Erlotinib Ketoconazole 2 2 -1.4 2
Selegiline Oral contraceptives 10–20 10–20 -0.25 3
Paclitaxel OC144-093 (ONT-093) 1.5 2 NR 4
Simvastatin Imatinib 2 3.5 NR 5
Rosuvastatin Gemfibrozil 1.88 2.21 -1 6
Rosuvastatin Lopinavir/ritonavir 2.1 4.7 -1.2 7
Rosuvastatin Ciclosporin 7.1 10.6 -1 8
Everolimus Ciclosporinc 1.74 1.06 0.5 9
Everolimus Ciclosporind 2.68 1.82 0 9
Paroxetine Terbinafine 2.5 1.9 NR 10
Desipramine Terbinafine 5 2 NR 11
Duloxetine Fluvoxamine 6 2.5 NR 12
Levacetylmethadol Ketoconazole 5.29 3.22 -0.09 13
Atomoxetine Paroxetine or fluoxetine 6–8 3–4 NR 14
Repaglinide Gemfibrozil 7.0 2.0 NR 15
Sirolimus Posaconazole 8.9 6.7 1 16
Saquinavir Ritonavir 128.9 32.5 0.8 17
Salmeterol Ketoconazole 16 1.4 NR 18
a This is the drug that is studied to determine if its exposure is changed by the presence of another drug, which is termed COMED.
b AUC fold and Cmax fold are the ratios between the exposure in the presence of COMED and that in the absence of COMED. AUC fold =AUC
(with COMED)/AUC (without COMED); Cmax fold =Cmax (with COMED)/Cmax (without COMED).
c Sandimmune formulation: a gelatin capsule filled with a corn oil suspension.
d Neoral formulation: a gelatin capsule filled with a microemulsion preconcentrate.
AUC = area under the plasma concentration vs time curve; Cmax=maximum plasma concentration; COMED = concomitant medication;
NR= not reported; tmax = time to Cmax.
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If we have a better understanding of this
phenomenon, it will be greatly helpful to clinical
interpretation of the observed DDI. Further-
more, if we can predict the relative change of
AUC, Cmax and tmax based on the information
available, it will be more valuable. This study
intends to make such an attempt for didactical
purposes. By assuming that the DDI was a result
of changes of primary parameters of the drug of
interest, the relative changes of AUC, Cmax and
tmax were investigated by various simulations.
Methods
The important steps of this study included:
setting up the model and specifications; im-
plementation of the model by simulations; and
data analyses and result interpretations.
The Assumptions
This study made the following assumptions.
1. DDI was considered as pharmacokinetic
interaction and no pharmacodynamic interaction
was involved.
2. DDI resulted in changes of one or more of the
primary pharmacokinetic parameters of the drug
of interest, such as absorption constant (ka),
bioavailability (F), volume of distribution (Vd)
and clearance (CL), which, in turn, altered the
secondary parameters, such as AUC, Cmax and
tmax. Based on this assumption, COMEDwas not
specified in all the simulations performed regard-
ing its dosage amount, dosing time, dosing
frequency and dose titration scheme. However,
the changes of the primary parameters of the
drug of interest were considered to be the
reflections of the combinations of all these
factors.
3. The pharmacokinetics were assumed to fol-
low a single dose, one-compartment model with
first-order absorption and first-order elimination
for oral administration route.
Pharmacokinetic Model
A pharmacokinetic model loosely based on
midazolam in vivo characteristics was selected.
The model was described by the formula in
equation (1):
C ¼ F Dose  ka
Vdðka  CL=VdÞ
 ðeCL=Vd  t  eka  tÞ
(Eq: 1Þ
where C is the plasma drug concentration at t, the
time elapsed after the dosage administration of
the amount (Dose).
This model and associated parameters were
for the drug of interest only. For COMED, no
specific model and parameters were needed
according to assumption (2). The CL, F, Vd, and
ka of the drug of interest would be changed to
reflect the effects of COMED (see Simulations
and Glossary sections).
Simulations
The model parameters of CL and Vd were se-
lected from a collection of drugs with different























Fig. 1. The selection of parameters of clearance (CL) and volume of
distribution (Vd). CL (y-axis) and Vd (x-axis) vary widely. The diag-
onal lines show the combinations of CL and Vd with the same half-
lives (in hours, labeled near the lines). The selected combinations of
parameters are represented by different symbols.
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various combination values of CL and Vd were
located in several half-life zones.[22] One or
two combinations (in case of two, one with higher
CL and another with lower CL with similar half-
lives) of CL and Vd values were selected from
each zone.
For each combination of CL and Vd, there
were three levels of ka values (0.2, 1 and 5 h
-1,
respectively). F value was chosen as 0.2. There
were a total of 24 cases as summarized in table II.
For each case, the model parameters and the
simulation specifications varied as shown in
table III for Case 2 as an example. Other cases
used the same values except the second column
(‘Value’). The ‘Value’ column was referred to the
parameter values when the drug of interest was
administered alone. When this drug was ad-
ministered with COMED, these parameters
would change. The possible values after change
are listed in the third column (‘Values with
COMED’). Twenty-five simulations were con-
ducted for each of the four parameters (CL, F, ka
and Vd) in each of the 24 cases. Therefore, there
were a total of 2400 simulations conducted.
The time values were selected from the interval
between 0 to 580 hours for the first 15 cases. The
rest of the cases used much longer intervals
(58 000 hours for Cases 16–21 and 580 000 hours
for the last three cases). These intervals were
chosen with a consideration that most of the sim-
ulated profiles would be captured in order to
get a relatively accurate AUC calculation by
using trapezoidal method (zero to last timepoint).
To get a smooth curve and relatively more accu-
rate AUC, the interval between two adjacent
timepoints was chosen to be 0.1 hours.
Simulations were conducted for each of the
values of CL, F, Vd and ka using R program
(version 2.8, R project group). For every scenar-
io, concentration-time profile was generated and
the Cmax, tmax and AUC were calculated.
R packages including ‘base’, ‘stats’, ‘graphics’
and ‘lattice’ were used for AUC, Cmax and tmax
calculations, and for plotting the data. Several
functions were defined, such as AUC to last
timepoint (AUCt) and AUC to infinity (AUC¥)
according to the trapezoid rule as shown in




C  dt  Dt  ðCt0=2þ Ct1





where Ct0, Ct1,y, Ct refer to the concentrations
at initial timepoint (0), timepoint 1 and so on,
until timepoint t.
Cmax and tmax were identified by R using max()
function. The values of AUC, Cmax and tmax were
calculated for each scenario.
To investigate the situation where different
parameters changed simultaneously, another set
of simulations was conducted for Case 2, in which
every combination of the four parameter fold
changes were simulated as shown in table IV. In
Table II. Model parameters cases
Case # F ka (h-1) CL (L/h) Vd (L) Half-life (h)
1 0.2 0.2 38 260 4.74
2 0.2 1 38 260 4.74
3 0.2 5 38 260 4.74
4 0.2 0.2 48 20.8 0.30
5 0.2 1 48 20.8 0.30
6 0.2 5 48 20.8 0.30
7 0.2 0.2 4.88 12.8 1.82
8 0.2 1 4.88 12.8 1.82
9 0.2 5 4.88 12.8 1.82
10 0.2 0.2 0.28 18 44.55
11 0.2 1 0.28 18 44.55
12 0.2 5 0.28 18 44.55
13 0.2 0.2 68 2800 28.54
14 0.2 1 68 2800 28.54
15 0.2 5 68 2800 28.54
16 0.2 0.2 11 5800 365.40
17 0.2 1 11 5800 365.40
18 0.2 5 11 5800 365.40
19 0.2 0.2 0.2 88 304.92
20 0.2 1 0.2 88 304.92
21 0.2 5 0.2 88 304.92
22 0.2 0.2 0.158 3880 17 018
23 0.2 1 0.158 3880 17 018
24 0.2 5 0.158 3880 17 018
CL = clearance; F = bioavailability; ka= absorption rate constant;
Vd= volume of distribution.
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table IV, each parameter had five levels and there
were 625 (54) possible combinations. Similar to
the first set, simulations were conducted using the
R program. For every scenario, the concentra-
tion-time profile was generated, and the Cmax,
tmax and AUC were calculated.
Glossary
To facilitate the discussion, it would be bene-
ficial to define certain terms used in this study.
Standard Parameters. The standard setting for
the simulation, the scenario where no COMED
was used and the parameters of the drug of in-
terest were not changed. For example of Case 2,
the standard setting was given in the second col-
umn of table III: CL = 38 h/L, F= 0.2, ka = 1 h-1
and Vd = 260L. The standard parameters for
other cases can be found in table II.
Parameter Fold Changes. The ratios of the
parameters in a specific simulation scenario to
those of the standard setting when the parameters
were not less than the standard parameters.
Otherwise (i.e. the parameters in simulation were
less than the standard parameters), they were
referred to the negative ratios of the standard
parameters to the parameters used in a simula-
tion scenario. For example, the CL fold change
was defined as the ratios of the CL used for a
specific simulation to the standard CL (e.g.
38L/h for Case 2) when CL was not less than the
standard. If CL is less than the standard, the
CL fold change was defined as the negative ratio
of the standard CL (38L/h for Case 2) to the
CL used in the simulation (CLsim) as shown in
equation (4).
WhenCLsim  38;
CL fold change ¼ CLsim=38
WhenCLsim<38;
CL fold change ¼ 38=CLsim
(Eq: 4Þ
where CLsim was the value of CL in a specific
simulation scenario.
Similarly, F fold change was defined as shown
in equation (5).
WhenFsim  0:2;
Ffold change ¼ Fsim=0:2
WhenFsim<0:2;
Ffold change ¼ 0:2=Fsim
(Eq: 5Þ
where Fsim was the value of F in a specific simu-
lation scenario.
Vd fold change was defined as shown in
equation (6).
WhenVd;sim  260;
Vd fold change ¼ Vd;sim=260
WhenVd;sim<260;
Vd fold change ¼ 260=Vd;sim
(Eq: 6Þ
where Vd,sim was the value of Vd in a specific sim-
ulation scenario.
Table III. Simulation model parameters
Parameter Value Values with COMED Justification
Dose (mg) 5 5 One of the midazolam clinical doses
ka (1/h) 1 0.02, 1/n11,y, 1/n1, 1, n1 · 1,y, n11· 1, 50a Low (1/50) to high (50·) around 1
F 0.2 0.04, 0.2/n11,y, 0.2/n1, 0.2, n1 · 0.2,y, n11 ·0.2, 1.0b Low (1/5) to high (5·) around 0.2
CL (L/h) 38 0.76, 38/n11,y, 38/n1, 38, n1· 38,y, n11· 38, 1900a Low (1/50) to high (50·) around 38
Vd (L) 260 0.11, 260/n11,y, 260/n1, 260, n1· 260,y, n11· 260, 13 000a Low (1/50) to high (50·) around 260
a n1, n2, ..., n10, n11 represent 11 numbers from 1 to 50, evenly spaced between subsequent numbers. Therefore, there are a series of 25
numbers centered at the defaults shown in the ‘Value’ column. On the right side, there are 12 numbers greater than the defaults (the
‘Value’), which are n1 ·Value, n2·Value,y, n10·Value, n11 ·Value, and 50 ·Value. On the left side, there are another 12 numbers,
which are fractions of the Value: Value/50, Value/n11, Value/n10,y, Value/n2, and Value/n1.
b n1, n2, ..., n10, n11 have the similar meaning as in footnote a except that they represent 11 numbers from 1 to 5 considering the
bioavailability limit (0 to 1).
CL = clearance; COMED = concomitant medication; F =bioavailability; ka= absorption rate constant; Vd= volume of distribution.
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ka fold change was defined as shown in
equation (7).
When ka;sim  1;
ka fold change ¼ ka;sim=1
When ka;sim<1;
ka fold change ¼ 1=ka;sim
(Eq: 7Þ
where ka,sim was the value of ka in a specific sim-
ulation scenario.
Note that the standard parameters for Case 2
(CL = 38L/h, F = 0.2, ka = 1 h-1 and Vd = 260L)
were used for illustration purpose. A set of spe-
cific standard parameters (see table II) were used
in each specific case.
In this study, F fold changes were set at -5y,1,
y, 5. The other parameter fold changes (CL fold
change, Vd fold change and ka fold change) were
set to -50, y, 1, y, and 50, for the first set of
simulations (see table III) and -5, -2, 1, 2, 5 for
the second set of simulations (see table IV).
Standard Exposures. The exposures resulted
from the standard parameters (defined above),
including standard AUC¥ (AUC¥,std), standard
Cmax (Cmax,std) and standard tmax (tmax,std).
Exposure Changes. The ratios of the exposures
resulted from a simulated scenario to the
standard exposures (defined above). The AUC
fold change and Cmax fold change were defined in
a fashion similar to parameter fold changes as
shown in equations (8) and (9).
WhenAUC1;sim  AUC1;std;
AUC fold change ¼ AUC1;sim=AUC1;std
WhenAUC1;sim<AUC1;std;
AUC fold change ¼ AUC1;std=AUC1;sim
(Eq: 8Þ
where AUC¥,sim was the value of AUC¥ in a
specific simulation scenario.
WhenCmax;sim  Cmax;std;
Cmax fold change ¼ Cmax;sim=Cmax;std
WhenCmax;sim <Cmax;std;
Cmax fold change ¼ Cmax;std=Cmax;sim
(Eq: 9Þ
where Cmax.,sim was the value of Cmax in a specific
simulation scenario.
Please note that by using fold changes, the in-
creases were represented by the number >1 while
the decreases were referred to negative values less
than -1.
The tmax change was defined as the dif-
ference between (tmax)sim and tmax,std as shown in
equation (10).
tmax change ¼ tmax;sim  tmax;std (Eq: 10Þ
where tmax,sim was the value of tmax in a specific
simulation scenario.
Fold Change Difference. The differences be-
tween AUC fold change and Cmax fold change as
shown in equation (11).
Fold change difference ¼
AUC fold change Cmax fold change ðEq: 11Þ
Data Analyses
Parameter Fold Change, Exposure Fold Change
and Fold Change Difference Calculation
During the simulations, the parameter fold
changes (including CL fold change, F fold
change, Vd fold change and ka fold change), the
exposure fold changes (including AUC fold
change, Cmax fold change and tmax change) and
the fold change difference were calculated for each
scenario. Upon the iteration of the simulations,
Table IV. Model parameters for the second set of simulations
Parameter Value Values with COMED Justification
Dose (mg) 5 One of the midazolam clinical dose
ka (1/h) 1 0.2, 0.5, 1, 2, 5 From low (1/5) to high (5·) around 1
F 0.2 0.05, 0.1, 0.2, 0.4, 1.0 From low (1/5) to high (5·) around 0.2
CL (L/h) 38 7.6, 19, 38, 76, 190 From low (1/5) to high (5·) around 38
Vd (L) 260 52, 130, 260, 520, 1300 From low (1/5) to high (5·) around 260
CL = clearance; COMED = concomitant medication; F =bioavailability; ka= absorption rate constant; Vd= volume of distribution.
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a data sheet was accumulated to record the pa-
rameters (CL, F, Vd and ka) used, resulted AUC,
Cmax and tmax, and calculated parameter fold
changes, exposure fold changes and fold change
differences. The data sheet was used for generat-
ing plots.
Plots Generation
Based on the results of the above calculations,
the following plots were generated for the first set
of simulations.
 The concentration-time profiles for all scenar-
ios in each case were plotted.
 Exposure changes (including fold change
difference, AUC fold change, Cmax fold
change and tmax change) were plotted against
each parameter fold changes (including F fold
change, CL fold change, ka fold change and Vd
fold change).
The following plots were generated for the
second set of simulations.
 The fold change difference was plotted against
each of the parameter fold changes to investi-
gate the influencing parameters in the separa-
tion of AUC¥ fold changes and Cmax fold
changes.
 The AUC fold change was plotted against
each of the parameter fold changes.
 The Cmax fold change was plotted against each
of the parameter fold changes.
 The tmax change was plotted against each of
the parameter fold changes.
 After the major influencing parameters were
identified, the AUC fold change was examined
against both CL fold change and F fold
change in a 3-dimensional plot.
Results
The Simulated Profiles
For the first set of simulations, there were a
total of 2400 concentration-time profiles accom-
modated in 96 pages. A representative page is
shown in figure S1 in the Supplemental Digital
Content 1, http://links.adisonline.com/DRZ/A1.
For the second set of simulations, the con-
centration-time profiles for each combination of
different values of CL, F, Vd and ka were gener-
ated. There were a total of 625 profiles ac-
commodated in 25 pages. A representative page
including the standard profile (using Standard
Parameters, with a circle in the figure) is shown in
figure S2 in the Supplemental Digital Content.
The Effects of Parameter Fold Changes on
Exposure Changes
For the first set of simulations, 96 plots for the
exposure changes against parameter fold changes
were generated. Figure 2 shows the plots of the
exposure changes against CL fold changes for
Cases 4–6 and Cases 10–12. Figure 3 shows the
plots of the exposure changes against Vd fold
changes for Cases 13–15 and Cases 19–21. Figure 4
shows the plots of the exposure changes against
ka fold changes for Cases 2, 5 and 11. Figure 5
shows the exposure changes against F fold
changes for all cases.
The results from the second set were consistent
with those from the first set of simulations.
Figures S3–S6 in the Supplemental Digital Con-
tent show the effect of different parameter
fold changes on AUC fold change, Cmax fold
change, tmax Change, and fold change difference,
respectively.
Area Under the Plasma Concentration versus Time
Curve (AUC) Fold Change
For the first set of simulations, AUC fold
change decreased with CL fold changes and
increased with F fold changes, while it was not
affected by Vd fold changes and ka fold changes
as shown in figures 2–5.
For the second set, figure S3 in the Supple-
mental Digital Content indicated that the AUC
fold change was not affected by ka and Vd evi-
denced by the fact that AUC fold change could be
anywhere in the whole range regardless of ka fold
change or Vd fold change. As a result, AUC
fold change would be determined by CL and
F fold changes as shown in figure S7 in the Sup-
plemental Digital Content. When CL fold change
decreased to the lowest (-5-fold in the second
set of simulations) and F fold change increased
to the highest (5-fold in the second set of
simulations), the AUC fold change was the most
pronounced.
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These effects were expected and straightfor-
ward according to equation (12).
AUC ¼ FDose
CL ðEq: 12Þ
Maximum Plasma Concentration (Cmax) Fold
Change
Cmax fold change was more complex, which
was the major factor accounting for the varied
fold change difference.
The effect of F fold changes on Cmax fold
change was the most obvious one. As shown in
figure 5, Cmax fold change was proportional to F
fold change. Since AUC fold change was also
proportional to F fold change as shown in equa-
tion (12), if a DDI only caused F Change (no CL,
Vd or ka changes), the AUC fold change and Cmax
fold change would be exactly the same and the
fold change difference would be zero (figure 5).
Although Cmax fold change was in the same di-
rection as the F fold change, the exact pro-
portionality was not shown as indicated in the
upper right panel of figure S4 in the Supplemental
Digital Content. The reason was that the second
set of simulation used the same standard
parameters and the resulted standard exposures
for all possible combinations. Therefore, the
relationships between the parameter fold changes
and the exposure changes were in a range,
not a single line. Due to the same reason,
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CL = 48 L/h
Vd = 20.8 L, F = 0.2
ka = 0.2 h−1
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CL = 48 L/h
Vd = 20.8 L, F = 0.2
ka = 1 h−1
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CL = 48 L/h
Vd = 20.8 L, F = 0.2
ka = 5 h−1
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CL = 0.28 L/h
Vd = 18 L, F = 0.2
ka = 0.2 h−1
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CL = 0.28 L/h
Vd = 18 L, F = 0.2
ka = 1 h−1
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CL = 0.28 L/h
Vd = 18 L, F = 0.2



















Fig. 2. The plots of area under the plasma concentration vs time curve (AUC) and maximum plasma concentration (Cmax) fold changes, fold
change difference and time to Cmax (tmax) change against clearance (CL) fold changes. The case number and corresponding standard
parameters are labeled. Note that the y-axis labeled 1(0) indicates 1 for AUC fold change and Cmax fold change, while it is 0 for fold change
difference and tmax. F =bioavailability; ka= absorption rate constant; Vd= volume of distribution.
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unlike the one shown in figure 5, the relationship
between the fold change difference and F fold
change in the upper right panel in figure S6 in
the Supplemental Digital Content was not a
horizontal line.
The effect of CL fold change on Cmax fold
change seemed generally small, especially for the
drugs with long half-life and/or quick absorption.
In figure 2, the difference in Cmax fold change
among different panels can be appreciated. The
lower three panels with longer half-life had
minimal Cmax fold change, while for those in the
upper row with shorter half-life, the Cmax fold
change was significant. On the other hand, the
panels on the left with smaller ka values showed
larger Cmax fold change, while the panels on the
right with larger ka values had smaller Cmax fold
change, with the panel at lower right corner
having an almost straight horizontal line in-
dicating little effect on the Cmax fold change.
Another interesting fact was that the Cmax fold
change resulting from an increase of CL fold
change was quite different from that resulting
from a decrease of CL fold change. Taking the
panel at upper left corner as an example, increase
of CL fold change caused decrease of Cmax fold
change with a steep slope whereas decreases of
CL fold change induced a shallow increase of
Cmax fold change. This difference was not so ob-
vious in the upper left panel of figure S4 in the
Supplemental Digital Content due to two rea-
sons: (i) the second set of simulation was taking
Case 2 in the first set as basis and therefore the
range was not wide enough; and (ii) the multiple



























CL = 68 L/h
Vd = 2800 L, F = 0.2
ka = 0.2 h−1
Case 19
CL = 0.2 L/h
Vd = 88 L, F = 0.2
ka = 0.2 h−1
Case 14
CL = 68 L/h
Vd = 2800 L, F = 0.2
ka = 1 h−1
Case 15
CL = 68 L/h
Vd = 2800 L, F = 0.2
ka = 5 h−1
Case 20
CL = 0.2 L/h
Vd = 88 L, F = 0.2
ka = 1 h−1
Case 21
CL = 0.2 L/h
Vd = 88 L, F = 0.2















Fig. 3. The plots of area under the concentration curve (AUC) and maximum concentration (Cmax) fold changes, fold change difference and
time to Cmax (tmax) change against volume of distribution (Vd) fold changes. The case number and corresponding standard parameters are
labeled. Note that the y-axis labeled 1(0) indicates 1 for AUC fold change and Cmax fold change while it is 0 for fold change difference and tmax
change. F =bioavailability; ka= absorption constant.
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parameters were considered simultaneously,
which may compensate for each other.
The effect of ka fold change on Cmax fold
change was related to half-life as previously dis-
cussed and also as seen in figure 4. The standard
parameter of ka was all the same (1 h
-1) for the
three panels in figure 4. The middle panel with
shortest half-life produced the most prominent
effect on Cmax fold change when ka fold change
decreased, whereas the effect was much shallower
for the right panel with longest half-life among
the three cases. In addition, the different effects
on Cmax fold change between the movement of
ka fold change towards a positive direction (in-
crease) and a negative direction (decrease) were
observed. For the drugs with shorter half-life, the
middle panel of figure 4, for example, the slope of
the curve for the Cmax fold change against ka fold
change in the negative direction was steep, while
it was much shallower in the positive direction,
and even leveled off in the other two panels. Since
AUC fold change was not affected by ka fold
change, the effect of ka fold change on the fold
change difference was dependent on its effect on
Cmax fold change. Roughly, the fold change dif-
ference curve was a mirror image of Cmax fold
change, symmetric to the horizontal line at 1 (or 0).
A general trend between ka fold change and Cmax
fold change consistent with this observation was
seen for multiple parameter analysis as shown in
the lower left panel in figure S4 in the Supple-
mental Digital Content.
The curve representing the effect of Vd fold
change on Cmax fold change was also related to
half-life and ka fold change, especially the curve
shape when the Vd fold change moved to the ne-
gative direction as shown in figure 3. When the
half-life was shorter and ka was smaller, this part
of the curve leveled off as shown in the lower left
panel. Along with the increase of half-life and ka,
the curve became steeper until it straightened up
as shown in the upper right panel. Again, due to
the stable AUC fold change, the curve for fold
change difference was roughly a mirror image of
the curve for Cmax fold change. When multiple
parameters were considered simultaneously, the
general trend between Vd fold change and Cmax
fold change was consistent with this observation
as shown in the lower right panel of figures S4
and S6 in the Supplemental Digital Content.
Time to Reach Cmax (tmax) Changes
Similar to Cmax fold change, tmax change was
affected by multiple parameters, although F fold

























CL = 38 L/h
Vd = 260 L, F = 0.2
ka = 1 h−1
Case 5
CL = 48 L/h
Vd = 20.8 L, F = 0.2
ka = 1 h−1
Case 11
CL = 0.28 L/h
Vd = 18 L, F = 0.2





Fig. 4. The plots of area under the plasma concentration vs time curve (AUC) and maximum plasma concentration (Cmax) fold changes, fold
change difference, and time to Cmax (tmax) change against absorption rate constant (ka) fold changes. The case number and corresponding
standard parameters are labeled. Note that the y-axis labeled 1(0) indicates 1 for AUC fold change and Cmax fold change while it is 0 for fold
change difference and tmax change. F =bioavailability; Vd= volume of distribution.
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change did not have any effect as shown in figure
5 and the upper right panel in figure S5 in the
Supplemental Digital Content. Both the effects of
CL fold change and Vd fold change on tmax
change were dependent on ka values with smaller
ka having more significant effects as shown in
figures 2 and 3. Although the effects of half-life
could be appreciated in these two figures, the ef-
fects were more prominent when the effects of ka
fold change on tmax change was considered. As
shown in figure 4, for the drug with shorter half-
life (the middle panel), ka fold change caused less
tmax change compared to the tmax change for the
drug with longer half-life (the right panel in figure
S5 in the Supplemental Digital Content). For
both cases, the negative ka fold change produced
much larger tmax change compared to the posi-
tive ka fold change as seen from both figure 4 and
the lower left panel in figure S5 in the Supple-
mental Digital Content. It seemed that there was
a threshold for the decrease of tmax Change when
the ka fold change going higher in the positive
territory. The threshold value was also related to
the half-life and the standard parameter of ka
with smaller ka and longer half-life having more
prominent threshold.
Discussion
Due to the wide range of the fold changes of
the primary parameters, the length of the sam-
pling time was of concern to capture the major
part of the profiles for the purpose of accurate
calculations. As shown in figures S1 and S2 in the
Supplemental Digital Content, most of the pro-
files were well within the length of the sampling
time. Visual inspections for other pages for both
the first and second set of simulations were con-
ducted to ensure it was the case for all scenarios.
However, it was the author’s experience that the
interval between adjacent sampling times was
more important than the length of the sampling
time. Because the accuracy of the calculations
was of concern, the interval was set to 0.1 hour,
which seemed to be adequate.
Instead of modeling for both the drug of in-
terest and the COMED, the current approach
examined the parameter changes of the drug of
interest only. The purpose of the proposed ap-
proach is to get a general idea about the possible
nature of the drug interaction by emphasizing the
integration of all information available. The stu-
dy provided visualizations for various exposure
changes. The observations indicated that AUC
was mainly influenced by CL and F, Cmax was
affected by all four parameters, and tmax was
mainly affected by CL and ka. F did little for tmax
and ka was unrelated to AUC. From each plot
alone, limited information was obtained. To get
better interpretation, an integration approach
should be taken.
The study was conducted with concentra-
tion on the individual factor considered in-
dependently (the first set of the simulations),
although multiple parameters were taken into
account (in the second set of simulations). In-























Fig. 5. The plots of area under the plasma concentration vs time
curve (AUC) and maximum plasma concentration (Cmax) fold chan-
ges, fold change difference, and time to Cmax (tmax) change against
bioavailability (F) fold changes. Note that the y-axis labeled 1(0)
indicates 1 for AUC fold change and Cmax fold change, while it is 0 for
fold change difference and tmax change. The diagonal lines for AUC
fold changes and Cmax fold changes are overlapped, and the hor-
izontal lines for fold change difference and tmax changes are also
overlapped.
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more realistic and practical. For example, when
the individual F fold change was considered in-
dependently, its effect on fold change difference
showed a horizontal line (figure 5). However,
when multiple parameters were taken into ac-
count simultaneously, the upper right panel in
figure S6 in the Supplemental Digital Content
provided a more realistic picture. Instead of a
line, a broader range was given. More interest-
ingly, the plot showed certain symmetry pattern.
The symmetry of the effects of F fold change on
the fold change difference in this case was caused
by the symmetries of its effects on AUC fold
changes (figure S3 in the Supplemental Digital
Content) and Cmax fold changes (figure S4 in the
Supplemental Digital Content). This symmetry
had two possible consequences. First, at each
level of F fold change, fold change difference had
equal chances to go in either direction. For ex-
ample, at level of 2 for F fold change, fold change
difference ranged from about -10 to +10. The
chances to go positive or negative were relatively
equal dependent on the other parameters. Sec-
ondly, the increase or decrease of F fold change
would have similar effects on fold change differ-
ence, with the centre point (F fold change = 1)
having the smallest effect. For example, a 2-fold
increase of F (F fold change = 2) would result in
similar effects as it would for a 2-fold decrease of
F (F fold change = -2). When F fold change was
relatively small, the fold change difference would
be smaller compared to the situation where F fold
changes were larger (the upper right panel of
figure S6 in the Supplemental Digital Content).
These consequences were important because
when interpreting the data, one had to notice that
a certain level of fold change difference observed
could have been caused by either increased or
decreased F fold changes.
With the importance of multiple parameter
simultaneous consideration in mind, the follow-
ing summary of the basic pattern of exposure
changes according to the effects of parameter
fold changes may be of help. Figure 6 was sum-
marized from the 96 plots of the 24 cases studied.
For the plot in each cell, the x-axis was the
parameter fold changes and the y-axis was the
exposure changes. The table can be read hor-
izontally for each of the exposure changes
affected by one of the parameter fold changes or
vertically for the effects of each parameter fold
changes on a specific exposure change. For ex-
ample, reading horizontally for the effects of Vd
fold change would result in the following.
 Decreased Vd fold change would cause a small
decrease of fold change difference, no effect on
AUC fold change, a small increase of Cmax
fold change and a modest decrease of tmax
change.
 Increased Vd fold would cause an increase of
fold change difference, no effect on AUC fold
change, a decrease of Cmax fold change and a
modest increase of tmax change.
To use this chart to interpret DDI, follow the




















Fig. 6. Basic pattern summary and pattern reasoning. The columns
and the ordinate in each cell show the exposure (fold change differ-
ence, area under the plasma concentration vs time curve [AUC] fold
change, maximum plasma concentration [Cmax] fold change and
time to Cmax [tmax] change), while the rows and the abscissa in each
cell show the parameter fold changes as labeled. The intersection of
the ordinate and the abscissa represents the situations when para-
meter fold changes are 1 (no change). The right side from this point
represents the parameter fold changes more than 1 (increase), while
the left side stands for the parameter fold changes less than -1
(decrease). The line indicates the exposure changes (fold change
difference, AUC fold change, Cmax fold change and tmax change)
when parameter fold changes increase (or decrease). Its slope sig-
nifies the extent of the changes. The shaded areas indicate the
consistency of exposure changes induced by a specific parameter
change, which provides the evidence for selecting the candidates for
the example in the study by Hsu et al.[17]
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DDI of saquinavir with coadministration of
ritonavir[17] is taken as an example.
1. Perform a drug interaction study and get the
values of AUC, Cmax and tmax in the presence and
the absence of COMED.
2. Calculate the AUC fold change, Cmax fold
change and tmax change. Get the fold change
difference. In the example, AUC fold change is
128.9, Cmax fold change is 32.5, tmax change is
0.8 h and the fold change difference is 96.4.
3. Find the candidates of parameter fold
changes, which account for the exposure changes
obtained from step 2. In the example, all the
exposure changes are positive. For this reason,
CL fold change could be a candidate because
decreased CL fold change would make all
exposure changes positive. However, Vd fold
change may not qualify the candidacy due to
the fact that although decreased Vd fold change
could cause an increase of Cmax fold change, it
would result in decreases of tmax change and fold
change difference based on figure 6. On the other
hand, although an increase of Vd fold change
could make tmax change and fold change differ-
ence positive, it would induce a decrease of Cmax
fold change. In addition, the increase of AUC
fold change is so significant in the example, while
figure 6 shows no change of AUC when Vd fold
change is altered. For the similar reasons, ka fold
change may be eliminated from the candidate
list. It is noted that there is a significant increase
of Cmax fold change (32.5). If reading the
chart vertically for the column of Cmax fold
change, significant increase of Cmax fold change
only occurs when there is an increase of F fold
change. Therefore, although the increase of F
fold change alone may not produce increases
of tmax change and fold change difference, its
contribution could not be ignored due to the
considerable increase of Cmax fold change. There-
fore, two potential candidates are selected. The
reasoning process can be found by the shaded
areas in figure 6.
4. Consider all available information to confirm
or reject the candidates. For the example,
saquinavir is primarily eliminated by means of
metabolism; only 3% of a 14C-labelled dose is
recovered in urine after intravenous administra-
tion.[23] In addition, the reported systemic plasma
CL of saquinavir is higher than hepatic plasma
flow. The absolute oral bioavailability of saqui-
navir is about 3%. Cytochrome P450 (CYP) 3A,
the major isoform in the metabolism of ritonavir
and saquinavir is present in intestinal tissue,[24,25]
in addition to the liver. Thus, it is likely that
saquinavir undergoes first-pass metabolism by
both intestinal and hepatic enzymes. Because of
this, coupled with the fact that ritonavir has a low
in vitro concentration that produced 50% inhibi-
tion (IC50), it would be expected that ritonavir
would have a marked inhibitory effect on the
first-pass metabolism of saquinavir. In contrast,
because the plasma CL of saquinavir approaches
or exceeds hepatic plasma flow rate, even though
ritonavir has a low in vitro IC50, it is likely that the
post-absorptive inhibition effect will not be large.
The information listed here tends to confirm the
candidates selected by figure 6. However, the
apparent controversy between a large AUC fold
change (128.9) and the relatively small effects of
CL fold change implied by the statements that the
post-absorptive inhibition effect will not be large
needs more explanation. Since the effects of CL
fold change on Cmax fold change are generally
small (figure 2), one may assume that the effect
observed for the Cmax fold change of saquinavir
is primarily caused by F fold change (i.e. the
suppression of the first-pass metabolism).
Ritonavir would then yield a significant inhibi-
tion of the first-pass metabolism, resulting in a
Cmax fold change of 32.5 and also an AUC fold
change of 32.5. If the net effect on AUC is the
product of first-pass and post-absorptive inhibi-
tion, then the latter corresponding inhibition can
be estimated to be 4 expressed as the AUC fold
change, which is relatively small and very close to
the reported estimate.[17]
It is important to understand the nature of
DDI in order to prevent its adverse consequences
if any. When a DDI is metabolism based, it is
critical to identify whether the DDI occurs at
pre-systemic level or systemic level. One of the
difficulties for such an interpretation is that the
absolute bioavailability (F) of a drug is usually
not readily available and furthermore, it is dif-
ficult to estimate the F changes during a DDI
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study. As a result, the proposed approach to
perform a rough estimate seems attractive. The
following potential applications of such a pattern
recognition approach may be anticipated.
1. A general understanding and a rough esti-
mate about the nature of the DDI observed may
be obtained from a simple comparison.
2. Based on the understanding of the mechan-
ism, the output can be predicted regarding which
exposure index is more prominent when it is of
concern. As mentioned earlier, for some drugs,
AUC is the major concern of exposure and for
others it is Cmax. Under certain circumstances,
tmax is also of concern.
3. This approach would be helpful to under-
stand any situation where AUC and Cmax have
differences, such as providing an explanation for
a failed bioequivalence study. In one scenario, the
AUC meets the criteria but Cmax does not, while
under another scenario, Cmax meets the criteria
but AUC does not. The pattern recognition
approach would suggest helpful hints to single
out the possible mechanism in order to decide
whether the differences between the test and
reference are caused by the formulation differ-
ences or some other influential factors. By the
same token, this pattern recognition approach
would also be useful for interpretations of other
similar studies, such as food effect study (with
and without food), renal impairment and hepatic
impairment studies (subject groups with different
renal or hepatic functions), where the AUC and
Cmax changes differ and tmax varies.
4. The approach would be beneficial for inter-
preting the exposure difference resulting from
different genetic makeup. For example, poor
metabolizers of CYP2D6 have a 10-fold higher
AUC and a 5-fold higher peak concentration to a
given dose of atomoxetine compared with ex-
tensive metabolizers.[14]
5. Manufacture parameters may affect the in
vivo performance. The pattern recognition ap-
proach will help the understanding of the effects
of the manufacture parameters.
It should be emphasized that this approach be
integrated with other methodologies due to its
limited abilities. The limitations for the current
study are listed below.
1. A linear, one-compartment model with first-
order elimination was assumed. The real world
might be more complex.Whenmetabolism-based
DDI is considered, saturation is frequently
observed. The drugs listed in table I might not
all follow the assumptions. With emphasizing the
general trend for common parameters related to
drug absorption, bioavailability and elimination,
caution should be exercised for assumption
violation.
2. The first-order absorption was used (constant
ka). It implied the unrealistic assumption that the
maximum absorption rate was achieved instan-
taneously. Due to its popularity and the fact that
in some cases it was sufficient to describe the
process of drug input, the current study used it
for easier interpretation.
3. Lag time, the delay between drug
administration and the beginning of absorption,
was not considered in this study. The lag time can
be anywhere from a few minutes to many hours.
It may be particularly important when a rapid
onset of effect is desired.
4. Single dose was used in all the simulations.
Multiple doses might be needed to show a
significant interaction. However, considering
that the purpose of this study was to compare
the exposure between the subjects with COMED
and those without, the single dose results could be
extrapolated to the case of multiple doses with a
linear assumption.
5. The results obtained from this approach
could be inconclusive. However, a general trend
is helpful, in principle. Furthermore, integration
with other methodologies for interpretation is
always advised.
Conclusion
With the assumptions that the primary para-
meters of a drug of interest are altered during a
DDI, an approach, named DDI pattern recogni-
tion for didactical purposes, is proposed for in-
terpreting the DDI results based on the exposure
fold changes. DDI pattern recognition may pro-
vide an insight of the mechanistic nature of DDI
and a general idea about the processes, which
dominate a DDI.
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This approach analyses DDI from a new
angle. Due to the complexity of DDI, one angle is
not enough. By emphasizing the integration of all
available information and mechanistic inter-
pretation frommultiple angles, the new approach
may play a significant role in interpreting DDI
studies.
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